Eli Lilly: LIBRETTO-431 Study Meets Primary Endpoint
(RTTNews) - Eli Lilly and Company (LLY) reported topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed - with or without pembrolizumab - as an initial treatment for patients with rearranged during transfection fusion-positive advanced or metastatic non-small cell lung cancer. The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival.
The company will present full results from the LIBRETTO-431 trial at an upcoming medical meeting, submitted to a peer-reviewed journal, and discussed with health authorities.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.